advertisement
11.4 Prostaglandins (14)
Showing records 1 to 14
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins56457 Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma
Lou H; Zong Y; Ge YR; Cheng JW; Wei RL
Current Medical Research and Opinion 2014; 30: 1367-1373
56363 Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions
Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 340-345
56669 An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial
Crichton AC; Nixon DR; Simonyi S; Bhogal M; Sigouin CS; Discepola MJ; Hutnik CM; Baptiste DC; Yan DB
Clinical Ophthalmology 2014; 8: 1031-1038
56193 Hypertension secondary to treatment with latanoprost
Santos-Bueso E; Sáenz-Francés F; Palmero-Fernández L; García-Sáenz S; Martínez-de-la-Casa JM; García-Feijoo J; García-Sánchez J
Archivos de la Sociedad Española de Oftalmologia 2015; 90: 37-39
56427 Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives
Marsovszky L; Resch MD; Visontai Z; Németh J
Pathology oncology research : POR 2014; 20: 741-746
56351 Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
Wang K; Yuan Z; Yao K; Zhao J; Xu L; Fang A; Zhang M; Wu L; Ji J; Hou J; Liu Q; Sun X
BMC Ophthalmology 2014; 14: 21
56086 Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution
Sakata R; Shirato S; Miyata K; Aihara M
Japanese Journal of Ophthalmology 2014; 58: 212-217
56362 The prostaglandin f2α analog fluprostenol attenuates the fibrotic effects of connective tissue growth factor on human trabecular meshwork cells
Fuchshofer R; Kuespert S; Junglas B; Tamm ER
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 237-245
56418 Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety
Kuwayama Y; Nomura A
Advances in Therapy 2014; 31: 461-471
56177 Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension
Sakurai M; Higashide T; Ohkubo S; Takeda H; Sugiyama K
British Journal of Ophthalmology 2014; 98: 469-473
56145 Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients
Figus M; Nardi M; Piaggi P; Sartini M; Guidi G; Martini L; Lazzeri S
Eye 2014; 28: 422-429
56517 A temperature-induced and shear-reversible assembly of latanoprost-loaded amphiphilic chitosan colloids: Characterization and in vivo glaucoma treatment
Hsiao MH; Chiou SH; Larsson M; Hung KH; Wang YL; Liu CJ; Liu DM
Acta biomaterialia 2014; 10: 3188-3196
56652 Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
Campbell JH; Schwartz GF; LaBounty B; Kowalski JW; Patel VD
Clinical Ophthalmology 2014; 8: 927-935
56592 Long-term efficacy of selective laser trabeculoplasty in patients on prostaglandin therapy
Hirn C; Zehnder S; Bauer G; Jaggi GP; Töteberg-Harms M; Zweifel SA; Lindegger DJ; Funk J
Klinische Monatsblätter für Augenheilkunde 2014; 231: 351-356
